Anthem, Inc. to Acquire MMM Holdings, LLC and Affiliates From InnovaCare Health, L.P.
Anthem, Inc. to Acquire MMM Holdings, LLC and Affiliates From InnovaCare Health, L.P. Anthem, Inc. (NYSE:ANTM) today announced that the company has entered into an agreement with InnovaCare Health, L.P., to acquire its Puerto Rico-based subsidiaries, including MMM Holdings, LLC (MMM) and its Medicare Advantage (MA) plan MMM Healthcare, LLC as well as affiliated companies and Medicaid plan. We are pleased to expand Anthems commitment to serve Medicare and Medicaid-eligible individuals and consumers to Puerto Rico. We remain focused on providing services that drive greater value while giving members access to care and services that meet their diverse needs, enhance their experience, and help them lead healthier lives, said Gail K. Boudreaux, President and CEO, Anthem, Inc.
(2)
REDWOOD CITY, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) A day after announcing their new immuno-oncology collaboration, Coherus BioSciences, Inc. (Nasdaq: CHRS) ( Coherus ) announced that Shanghai Junshi Biosciences Co., Ltd (HK: 1877; SH: 688180) ( Junshi Biosciences ) intends to make a strategic investment of $50 million in Coherus pursuant to the terms of the definitive stock purchase agreement. We view our collaboration with Coherus as a strategic long-term partnership for the development and commercialization of toripalimab and promising PD-1 combination candidates, said Dr. Ning LI, CEO of Junshi Biosciences. We wanted to invest in Coherus so we could share our future growth together and mutual success with these programs.
Press release content from Business Wire. The AP news staff was not involved in its creation.
BeiGene Announces Positive Topline Results for Global Phase 3 Trial of Tislelizumab in Esophageal Squamous Cell Carcinoma
January 27, 2021 GMT
CAMBRIDGE, Mass. & BEIJING (BUSINESS WIRE) Jan 27, 2021
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the global Phase 3 RATIONALE 302 trial of its anti-PD-1 antibody tislelizumab versus investigator’s choice chemotherapy in patients with advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who have received prior systemic treatment met its primary endpoint of overall survival (OS). In the trial results, tislelizumab demonstrated a statistically significant and clinically meaningful improvement in OS in the intention-to-treat (ITT) population, when compared to chemotherapy. The safety prof
Novartis International AG: Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene
Novartis secures development and commercialization rights in North America, Europe, and Japan
Accelerates Novartis immuno-oncology combination strategy with multiple potential tislelizumab plus Novartis therapy combinations
Tislelizumab already approved for patients with classical Hodgkin s lymphoma and metastatic urothelial carcinoma in China; 15 registration-enabling clinical trials under way in non-small cell lung cancer (NSCLC) and other solid tumors
Basel, January 11, 2021 - Novartis has signed a strategic collaboration agreement to in-license tislelizumab from BeiGene, Ltd. in major markets outside of China, accelerating the potential for Novartis to enter the large and growing checkpoint inhibitor field. Tislelizumab is an anti-PD-1 monoclonal antibody specifically designed to minimize binding to Fc?R on macrophages. In pre-clinical studies, binding to Fc?R on macro